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Abstract
Background: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa.
Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support
patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely
available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text
messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions
will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added
to usual care is limited.
Objective: The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving
health outcomes and medication adherence in patients with type 2 diabetes compared to an active control.
Methods: We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape
Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment
and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with
a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6
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weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and
complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin
A1c (HbA1c) levels as a marker for long-term blood glucose control and a secondary outcome of blood pressure control. We will
record the costs of performing these activities and estimate cost-effectiveness. We will also use process evaluation to capture the
collection of medication and assess the reception of the intervention by participants and health care workers.
Results: Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data
collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in
June 2019, followed by analysis and disclosing of group allocation.
Conclusions: The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness
of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence
for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a
wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for
informing people about the work and raise awareness of what is being developed and studied.
Trial Registration: ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite
at http://www.webcitation.org/786316Zqk)
International Registered Report Identifier (IRRID): DERR1-10.2196/12377
(JMIR Res Protoc 2019;8(6):e12377)   doi:10.2196/12377
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Introduction
The Global Health Importance of Diabetes Mellitus
Diabetes mellitus, specifically type 2 diabetes, is a major burden
to individuals and health care systems globally, including in
low-resource settings. Estimates of the prevalence of diabetes
in Southern Africa vary. A 2009 survey across South Africa
placed the incidence at 9% [1], but a survey in Cape Town
identified a rising prevalence with an age-adjusted prevalence
of 13.1% [2] in black Africans. The prevalence of diabetes is
also rising in Malawi with an incidence of 6% [3]. As the
prevalence of diabetes is rising, it is likely that the impact of
the associated premature mortality and morbidity through, for
example, visual impairment, renal dysfunction, neuropathy, and
cardiovascular disease will increase. However, failure to take
medicine as prescribed, often referred to as nonadherence, can
result in a failure to deliver the benefits of effective medical
treatments into better outcomes for individual patients. For
example, there is an association between better adherence to
treatment and better control and fewer complications for people
with type 2 diabetes [4,5].
The Need for Further Research and Interventions to
Improve Regular and Sustained Use of Medication
Reasons for not collecting or taking medications as intended
are well documented and include psychological factors, lack of
social support, low levels of health literacy, and interactions
with the health care system that do not support self-management
[6]. Medication adherence in sub-Saharan Africa is estimated
at around 64% [7]. Better understanding of treatments and
helping people deal with day-to-day challenges can improve
the collection and taking of medicines [8]. Interventions
delivered by short message service (SMS) text messaging have
been effective in increasing adherence to antiretroviral therapy
and other conditions [9,10]. More research is needed to develop
and test better ways to leverage widely used new technologies
to help people to improve their use of medicine.
Mobile Health-Based Support for People With
Long-Term Conditions
In a primary care setting in the Western Cape [11], we developed
a low-cost system of registering patients and regularly sending
health messages via SMS text messages. A randomized trial of
the intervention for people with high blood pressure—the
SMS-Text Adherence Support-Blood Pressure (StAR-BP) trial
[12]—showed better adherence and improved blood pressure
control for people receiving the SMS text messages compared
to those who received active control messages (ie, usual care
supplemented by noninformational text messaging). Our system
of sending text messages complies with the principles of the
information and communications technology policy frameworks
now being established in sub-Saharan countries, including the
South African mHealth Strategy [13]. For example, our system
aims to be integrated into routine care and simple in design. As
part of our work to understand the broader applicability of the
intervention for people with other chronic diseases, we are now
exploring its use for people with type 2 diabetes.
Our own recent focus group work and interviews alongside the
StAR-BP trial [14] confirm the importance of offering
evidence-based information to help with self-management of
long-term conditions. For example, lack of knowledge and
mixed feelings toward regular use of medicine to treat chronic
conditions, as well as difficulty in remembering to take them,
can lead to missing clinic appointments for medicine collection
and missing out on taking the tablets. Participants in the
StAR-BP trial told us how helpful the system was in reminding
them to collect and use their medication. They also told us it
encouraged them to make greater efforts to maintain their
general health [14].
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A systematic review of SMS text messaging in supporting
medication use in type 2 diabetes suggested significant benefits,
but there was substantial heterogeneity. A recent study in New
Zealand that included people with type 1 diabetes and type 2
diabetes with insulin treatment also suggested a benefit in
glycemic control. Other work has been carried out to evaluate
diabetes-focused SMS systems in low-resource settings where
very low rates of medication use offer potential for substantial
benefit. In a two-center comparison study in Senegal, text
messages were sent to people with diabetes over 3 months. A
6-month randomized trial in Bangladesh consisting of 256
patients identified a small but significant fall in hemoglobin A1c
(HbA1c) [15]. However, a longer study duration, the use of
structured message development, and studies in sub-Saharan
Africa are needed to reduce uncertainty.
We therefore adapted the message content for the StAR-BP
system to be appropriate for people with type 2 diabetes in two
sub-Saharan settings. Content was based on development work
to identify messages that could provide support through
behavior-change techniques as proposed by the Capability,
Opportunity, Motivation-Behavior (COM-B) framework, which
focuses on capability, opportunity, and motivation factors for
changing behavior [16-18]. We followed recommended
guidelines on SMS text message development, including testing
and adapting for local applicability as well as usefulness and
field-testing the intervention. Feedback was elicited from a
range of stakeholders, including diabetes patients, diabetes
health care staff, and experts, concerning promotion of a healthy
lifestyle, diet, and exercise in order to understand relevance,
usefulness, and acceptability of message content. The system
offers a new approach to improving access to care through
providing support to patients with diabetes alongside usual care.
In doing this development work, we followed the Medical
Research Council framework for developing and evaluating
complex interventions [16]. We have also used theory- and
evidence-informed behavior-change constructs to guide the
content and delivery mechanisms of the SMS text message
intervention in this setting [19]. The explicit use of this approach
for diabetes messaging in this context is novel [20]. We planned
to test effectiveness and cost-effectiveness of the system in
improving glycemic control using an individually randomized
controlled design with an embedded process evaluation.
Methods
Trial Aims and Objectives
The overall aim of the SMS-Text Adherence Support for Type
2 Diabetes (StAR2D) trial is to test the effectiveness of sending
SMS text messages in improving health outcomes and
medication adherence in patients with type 2 diabetes compared
to an active control. A secondary aim is to examine the
incremental cost and cost-effectiveness of the intervention. A
process evaluation using qualitative research methods will be
carried out alongside the trial to investigate participant responses
and acceptability.
Ethical Issues
The University of Oxford Tropical Research Ethics Committee
(OXTREC) approved the research protocol (reference number
22-15). Additionally, the University of Cape Town Human
Research Ethics Committee (UCT HREC) (reference number
126/2015) and the Malawi National Health Services Research
Committee (NHSRC) (reference number 15/7/1425) also
approved the protocol. The sponsor of this study—University
of Oxford—has put in place insurance in the event that any
participant suffers harm as a result of their involvement in the
research. This protocol refers to version 2.0 of the StAR2D trial
protocol, dated September 16, 2016, that was submitted
following formative work but before recruitment to the trial
began.
Trial Design
The trial is a 12-month, multicenter, two-parallel-arm,
individually randomized controlled trial. A flowchart showing
the sequence of recruitment, assessment, and intervention is
shown in Figure 1. A checklist of trial procedures is given in
Table 1.
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Figure 1. Trial flowchart. SMS: short message service.
Table 1. Visits and procedures to be performed during the trial.
VisitsProcedures
12-month visitFollow-up session with rou-
tine data and nonscheduled
research contacts
BaselineEligibility check
XEligibility assessment
Duration of diabetes
XDemographics: age, gender, language preference, and work status
XMedical history: comorbid conditions and duration of diabetes
XXXCurrent medication, including current oral glucose medication, doses,
use of insulin, and other medications
XXTobacco use
XXChanges in medication
XXPhysical examination: height and weight
XXHemoglobin A1c measurement
XXTotal and HDLa cholesterol
XXBlood pressure measurement
XXXMedication pickup
XXAdherence score
XPurchase of drugs during stock-out (ie, out of stock at clinic)
XXEuroQol 5-Dimension 3-Level
XXSatisfaction with care
XSelf-reported measures of eating and physical activity
XNonscheduled research contact
XXAdverse event assessment
XFailure to receive message
aHDL: high-density lipoprotein.
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Setting
Participants were recruited from publicly funded outpatient
facilities that treat people with type 2 diabetes. We identified
sites in Cape Town, South Africa, and Lilongwe, Malawi,
serving patients living in low- and middle-income settings. Both
are urban sites with a high burden of type 2 diabetes. In Cape
Town, recruitment was from two clinics serving townships to
the north of the city, and Lilongwe is the capital city of Malawi.
A high proportion of the population live in low-income informal
settlements where one clinic was involved in recruitment. In
both settings, patients received health care and medication from
a locally appropriate health care facility. Care is provided free
of charge and a limited range of essential medicines are available
at no cost to patients to reduce blood glucose and blood pressure.
Participant Eligibility, Recruitment, and Screening
Eligible patients were those with type 2 diabetes, aged 18 years
or greater, and taking an oral glucose-lowering medication.
Other inclusion criteria included the following: ability to
communicate in one of the predominant official languages
spoken in the Western Cape province in South Africa (English,
Afrikaans, or isiXhosa) and in Malawi (English or Chichewa
language); access to a mobile phone, where shared access is
allowed with permission of the phone owner; ability to use, or
be helped to use, the SMS text messaging feature on a mobile
phone, including knowing that a text message had been received
and reading it; and current and planned future residence in the
communities served by the participating clinics. The following
patients were ineligible for recruitment: patients who have been
admitted to hospital for hyperglycemia or hypoglycemia within
the previous 3 months; patients who are pregnant or within 3
months postpartum by self-report or with plans to become
pregnant in the next 12 months; patients with a terminal medical
condition; patients with another member of the household
already recruited to the trial; or patients who participated in
formative work for the intervention development.
Patients attending the clinic for their regular diabetes care were
provided with information about the trial at the regular education
sessions, on posters, and in leaflets. Clinic patients who attended
for routine diabetes care or to pick up diabetes medicine and
who have received information about the trial were asked if
they were interested in joining the trial.
Potential trial participants received verbal and written
information about the trial in their preferred language and had
the opportunity to speak to trained study research staff and ask
them questions. If they agreed to participate, they provided
verbal assent to screening procedures. If eligible, they then
provided written consent for enrolment and to enter the trial.
Copies of the consent forms were given to participants and
randomization was not carried out until confirmation that a
“welcome” text message had been received.
Data were transmitted using a low-cost, advanced-feature mobile
phone (ie, smartphone) acting as the trial data collection system.
A secure implementation of Sana (MIT), which ran on the
mobile phone, was linked to a secure server running Open
Medical Records System (OpenMRS) [21] using secure
information exchange protocols. This allowed errors in data
entry to be checked and enabled immediate upload of data to
the trial server.
Randomization
We used a remote Web-based randomization program, Sortition
(Oxford), minimizing for time since diagnosis, age, sex, and
trial site. Adults with type 2 diabetes were allocated in a 1:1
ratio to receive automated text message support or usual care
supplemented by active control. Allocations were directly
uploaded into the OpenMRS database to avoid creation of
locally held records. Randomization was carried out remotely
and independently of the clinic and local research staff. No
arrangements for unblinding during the trial were made.
Trial Outcomes and Other Measures
The primary outcome of the trial is the change in HbA1c from
baseline to 1 year. Secondary clinical outcomes are the
proportion of patients collecting 80% or more of their
agreed-upon, diabetes-related medication derived from routine
clinic data [22]; change in systolic blood pressure; change in
lipids; a combined measure of cardiovascular risk based on
HbA1c, lipids, and systolic blood pressure [23]; and the
proportion of the participants reaching treatment goals (ie, HbA1c
<8% and systolic blood pressure <140 mmHg).
The EuroQol 5-Dimension 3-Level (EQ-5D-3L) instrument
[24] and a locally adapted questionnaire to establish satisfaction
with treatment and delivery of treatment [25,26] were used and
available in all of the study languages. In addition, self-reported
medication-taking was recorded [27]. Basic demographic data
collected included age, sex, language preference, and work
status. Anthropometric measures were collected, including
measurement of height and weight using standard procedures
and self-reports of eating and physical activity, with a 7-day
recall.
Measurement and collection of data were carried out by a team
of research assistants trained and supervised to ensure
consistency between and within study sites with standard
operating procedures for clinical measurement.
Follow-Up Assessment
Annual follow-up is integrated with routine health care review.
At 12 months, a reminder text will be sent to invite participants
to attend their annual health care review and a final trial
assessment. Participants who do not attend the 12-month
follow-up clinic appointment will be followed up using the
mobile phone and other contact details; if the cause of
nonattendance is hospital admission or death, then hospital
records will be obtained.
Intervention
Trial participants allocated to the intervention group received
specifically designed text messages, including motivational and
educational messages. They also received prompts (ie,
reminders) about medication collection with timing personalized
by the information collected about all participants at the baseline
visit, from the clinic and pharmacy attendance. Messages were
sent three to four times a week for a period of 1 year. A message
was sent giving options to change the delivery time or language
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of messages. Messages were randomly selected from a library,
using rules that ensured individual messages were not repeated.
Messages were also personalized by information given about
smoking and use of alcohol. Full details of the intervention are
given in Multimedia Appendix 1. The intervention included
information intended to encourage people to take their medicine
regularly as prescribed. The intervention also prompted
participants when an anticipated attendance has not occurred
and informed them when an out-of-stock medicine was received
in the pharmacy and patients needed to return to obtain it. The
intervention is summarized in the Template for Intervention
Description and Replication (TIDieR) statement uploaded as
Multimedia Appendix 2.
Trial participants allocated to the usual care group received an
active control protocol: only noninformational text messages
were sent (eg, messages thanking the participant for taking part
in the study and a message on their birthday), alongside usual
care every 6 weeks. At both study sites, usual care consisted of
attendance to collect medication supplies at 2-monthly intervals
with review appointments where clinically indicated. Health
material on type 2 diabetes were available at all sites, which
included information about the importance of taking medicine
regularly, alongside other health information. Attendance at all
appointments by trial participants was tracked through routinely
implemented electronic and manual registers. Messages were
stopped at participant request.
Sample Size Estimation
We consider a minimum reduction in HbA1c, from baseline to
12 months, of 0.5% in this population clinically important and
feasible. A total of 814 participants (407 per group) across all
sites would be required to show a 0.5% reduction—assuming,
conservatively, a standard deviation of 2.2%—in this population
with 5%, two-sided significance level and power of 90% using
PASS software version 12 (NCSS). We have increased the
number to account for potential clustering between sites and
loss to follow-up of up to 20% to a total of 1066 (ie, 533 per
group). We will also have 90% power to detect a 10%-point
increase in adherence rate in the intervention group (ie, from
50% to 60%), including adjustment for clustering effects. We
plan to recruit half of the participants in each setting.
Analyses
The primary analysis will be carried out on the basis of
intention-to-treat (ITT) analysis. We will endeavor to obtain
full follow-up data on every participant to allow full ITT
analysis, but we expect missing data due to withdrawal, loss to
follow-up, or failure to attend clinic visits. The results from the
trial will be prepared as comparative summary statistics with
95% confidence intervals. All the tests will be done at a 5%,
two-sided significance level. The study results will be reported
in accordance with the Consolidated Standards of Reporting
Trials (CONSORT) 2010 statement. A full, detailed, statistical
analysis plan will be prepared and finalized before participant
follow-up is completed.
A linear regression model will be used to compare the primary
outcome (ie, change in HbA1c from baseline to 1 year) between
groups, adjusting for baseline HbA1c and minimizing variables.
Similar methods will be used to analyze blood pressure data
and other continuous outcomes. The proportion of people with
more than 80% proportion of days covered with medication will
be compared using adjusted logistic regression. We will carry
out a prespecified secondary analysis to compare outcomes in
individuals with uncontrolled diabetes (ie, HbA1c >8%) at
baseline.
Missing data will be reported with reasons given where available
and the missing data pattern and mechanism will be explored.
We will also carry out various sensitivity analyses using
alternative imputation methods to examine the robustness of
the results. Finally, we will use the regression method to
determine the factors influencing the impact of the intervention.
We will carry out subgroup analyses of the primary outcome
and adherence outcomes for the following subgroups: age (<55
years or ≥55 years); site (Cape Town or Lilongwe); sex (male
or female); number of years with type 2 diabetes (<7 years or
≥7 years); presence of one or more comorbidity (none, one, or
more); diabetes control at baseline (HbA1c ≤8% or >8%); and
self-reported adherence rating score at baseline (25 or <25).
Economic Analysis
The costing study will be based on data collected during the
trial and by using the trial findings. The costing study will
provide a descriptive account of the different cost components
annualized to take into account development and capital costs
in the form of a percentage increase in costs; the
cost-effectiveness study will model the system in terms of cost
per disability-adjusted life year (DALY) averted.
To assess the added cost per patient-year, the one-off design
costs will be excluded. Setup costs will be annualized over a
period of 10 years to reflect their potential for use in scale-up
and other applications and added to 1-year delivery costs. Capital
costs will be calculated by the replacement value of each item
and the estimated useful life and then annualized with a discount
rate of 3%. Costs will be adjusted for time using the consumer
price index. We will carry out a descriptive analysis of the
observed costs using standard methodologies. To assess
additional costs as a proportion of nonintervention delivery
costs per patient-year, total costs per treatment per patient-year
will be calculated.
Economic costs will include provider and patient costs.
Facility-level expenditure will include clinical staff, supplies,
and overhead (ie, capital, support staff, utilities, administration,
and management). Overhead will be calculated based on the
level of diabetes clinical activity as a share of the facility
activity. Number of visits, laboratory tests, and medication will
be collected from the project database. Besides facility costs,
costs associated with the SMS text messaging will be included.
One-off costs of the initial design of the system (ie, equipment
capital costs, staff, and supplies) will be identified. Research
costs, apart from that component of the formative research that
would be required if the intervention were rolled out to new
districts, will be excluded. Data sources will include interviews
with staff, facilities’ financial records (ie, staff packages and
unit costs of drugs, laboratory tests and other supplies, and
overheads), and financial records of the SMS organization.
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Patient costs will include recording the time spent in clinic and
asking about time spent travelling and costs of transport to the
clinic. These questions will only be asked once. The study
project manager and local coordinators will be interviewed to
validate the information.
The costing outcome will be the cost per patient-year and the
cost-effectiveness outcome will be incremental cost per DALY
averted [28,29].
Process Evaluation
The process evaluation is aimed at understanding
implementation of the intervention and contextual factors that
may explain the effects and applicability of the intervention. In
particular, we will explore the reach of and patient responses
to the intervention, including acceptability, in order to enhance
our understanding of why and how the intervention worked or
not and how it can be optimized in the future. Process measures
on the intervention reach and fidelity will be collected from the
SMS text message system where numbers of participants and
numbers of text messages sent and received are stored. At each
site, sources of data will be used to measure activity in the clinic
(eg, numbers attending the clinic) and the pharmacy. We will
also use these measures during the period of the study to identify
where problems might develop and to explore differences
between sites.
To explore how the intervention was received and responded
to, we will use semistructured interviews and focus groups with
purposive and convenience sampling of stakeholders, mainly
patient participants, but also clinic staff and representatives from
the relevant department of health involved with the study. We
will also conduct document reviews relating to the
implementation of the trial. Purposive sampling aims to explore
variation in response by variables, including age, gender, and
language group of patient participants. Patient participant
interviews will explore their experiences and views of receiving
SMS text messages; their responses (ie, thoughts, feeling, and
behaviors, especially in relation to the COM-B behavior-change
constructs); and other patient, environmental, and contextual
factors that may help us understand the trial outcomes and the
experience of participants.
The patient perception and experience component of the process
evaluation will be conducted at baseline, after enrolment and
before a participant is randomized, and at the end of the trial,
but before trial outcomes are known. We aim to interview the
same participants at baseline and at the end of the trial.
Allocation status of participants will be made known to only
the process evaluation researchers, with measures to avoid
unblinding the trial staff to individual allocation status. We will
also conduct two focus groups per site—one male and one
female—with a convenience sample of trial participants. Focus
groups will be used to achieve a better understanding of
experience by allowing a moderated exchange of views among
participants. A trained qualitative researcher using a topic guide
will carry out the in-depth interviews and focus groups; data
will be captured with field notes and through digital voice
recording and will be transcribed with anonymization. Notes
or transcripts will be coded and themes developed. Standard
approaches to ensuring the quality of the methodology will be
used, including dual review of transcripts, use of a coding
framework, and assessment of samples of dual-coded data.
Laboratory Measurement
HbA1c was measured using International Federation of Clinical
Chemistry calibrated analyzers linked to an international quality
assurance scheme at both sites. Total and high-density
lipoprotein (HDL) cholesterol was analyzed using an enzymatic
colorimetric method, again with an international quality
assurance scheme.
Data Management
Electronic data capture was be carried out using Sana (MIT)
utilizing low-cost Android mobile phones and a real-time,
mobile Internet connection to a server where the data will be
stored using OpenMRS [21]. Final locked versions of
deidentified data will be stored in SPSS Statistics for Windows,
version 25.0 (IBM Corp). Data records will be available for the
1066 patients recruited to the trial and, we estimate, a further
200 records containing data relating to assessed but ineligible
patients. All eligible patients will have two study visits. Data
management procedures will follow the detailed data
management plan submitted to the funders.
Quality Assurance Procedures: Bias, Concealment of
Allocation, and Attrition
A standardized presentation was delivered to participants
emphasizing the importance of lifestyle modification and
medicine in treating diabetes. We asked participants not to share
the content of their text messages and we did not recruit more
than one participant from the same household. Clinic staff do
not have access to information about allocated groups and will
not have the facility to send text messages to individuals through
the study system. Study procedures will be carried out by trained
research staff blinded to participant allocation group. Medication
dispensing data were collected blind to participant allocation.
Study outcomes will be assessed by laboratory staff with no
knowledge of treatment allocation or will be assessed by
research staff trained not to ask questions that would elicit group
allocation.
The study may be monitored or audited in accordance with the
current approved protocol—the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use-Good Clinical Practice (ICH
GCP)—relevant regulations, and standard operating procedures
by the sponsor or funder. The StAR2D Trial Steering Committee
and Data Monitoring Committee members are listed in the
Multimedia Appendix 3. The sponsor and funder will have no
role in interpretation of data or reporting of the trial.
Publication
The investigators will be involved in reviewing drafts of the
manuscripts, abstracts, press releases, and any other publications
arising from the study. Authors will acknowledge that the study
was funded by the UK Medical Research Council and the Global
Alliance for Chronic Disease. Authorship will be determined
in accordance with the International Committee of Medical
Journal Editors (ICMJE) guidelines and other contributors will
be acknowledged.
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Availability of Data and Materials
There are no data relating to this protocol publication; however,
following completion, datasets generated during the trial will
be available upon reasonable request.
Results
Recruitment to the trial began in September 2016 and follow-up
of participants was completed in October 2018. Data collection
from electronic health records and other routinely collected
sources is continuing. The database lock is anticipated in June
2019, followed by analysis and disclosing of group allocation.
Follow-up of participants at 1 year is complete and data
collection from routine sources is continuing. The database has
not been locked and trial allocation concealment remains intact.
Discussion
Type 2 diabetes is a major global health problem, including in
sub-Saharan Africa. This is putting additional strain on health
services that are often ill-equipped to deal with people with
diabetes and other noncommunicable diseases. Thus, there is a
need for novel approaches to support health services for people
in managing this and other chronic, lifestyle-associated
conditions. Digital technology has the potential to deliver
interventions at a low cost and at a wide scale. Small effects
have been observed in previous work [20,30]. Since this trial
was originally funded, further studies have confirmed the
potential for using SMS text messaging. A trial among people
with type 1 and type 2 diabetes in New Zealand has
demonstrated efficacy in reducing HbA1c [31]; in addition, a
study using a before-and-after design has demonstrated the
feasibility of text messaging in Senegal [32]. However, another
study in three countries did not identify a benefit from using
SMS text messages in its intervention [33].
This study allows us to explore the impact of SMS text
messaging for people with type 2 diabetes in two sub-Saharan
sites. The evaluation of effectiveness will provide information
about the potential impact of this strategy and its wider
cost-effectiveness. The formative work for this trial, along with
the process evaluation, will be published separately from the
effectiveness and cost-effectiveness evaluations. This study
builds on previous work [12], with an increased frequency of
messages and a message library utilizing a wide range of
behavior-change techniques and an increased number of content
domains [18]. SMS text messaging to deliver brief health-related
messages is a technology that is already expanding, as access
to Internet-based messaging becomes more widely adopted.
Nevertheless, the principle of sending brief messages has the
potential to be integrated, using a wide range of messaging
platforms, into routine care or implemented as add-on programs;
these could be particularly helpful for between-clinic visit
communication and support from health services.
This study focuses on the use of brief messages that could, if
necessary, be read by a friend or relative. We have, therefore,
not focused on literacy as a potential mediator of impact of the
intervention. Future work may need to be carried out to explore
the extent to which literacy is needed for this type of brief
intervention, although it will clearly be of importance where
more extensive use of digital devices is made.
Although this study targets people with type 2 diabetes, the
inclusion criteria are wide and do not exclude either participants
with comorbid conditions or those with a varied degree of
glycemic control. This study provides a further opportunity to
explore the potential for delivering care to people with a wider
range of cardiometabolic conditions [34], to look at the extent
to which the messages meet the different needs of individuals,
[35] and the extent to which this technology could be integrated
with other aspects of self-management and care delivery.
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